Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panion & Bf BiotechTPE:1760 -2.09%74 Pretax Margin % is 13.47% as of Dec. 2025, which is 12% above its 10-year median of 12.07. GuruFocus rates TPE:1760 with a GF Score™ of 74/100 and a GF Value™ of NT$96.03 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Panion & Bf Biotech ranks better than 68.47% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Panion & Bf Biotech Pretax Margin % Related Terms
Panion & Bf Biotech Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Panion & Bf Biotech's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1760 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Panion & Bf Biotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panion & Bf Biotech Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panion & Bf Biotech's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Panion & Bf Biotech's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panion & Bf Biotech (TPE:1760) has a Pretax Margin % of 13.47% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Panion & Bf Biotech and its competitors. This is 12% above median its historical median of 12.07. Over the past decade, Panion & Bf Biotech's Pretax Margin % has ranged from 5.70 to 17.35. According to the industry distribution chart, Panion & Bf Biotech ranks #303 out of 961 companies in the Drug Manufacturers industry, placing it in the top 31.5%.
Is Panion & Bf Biotech's Pretax Margin % too high?
Panion & Bf Biotech's current Pretax Margin % of 13.47% is 12% above median its 10-year median of 12.07. Over the past 10 years, this metric has ranged from a low of 5.70 to a high of 17.35. The Drug Manufacturers industry median Pretax Margin % is 7.28. Panion & Bf Biotech's value of 13.47% is 85% above this industry median. Based on the distribution chart, Panion & Bf Biotech ranks #303 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Panion & Bf Biotech has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's Pretax Margin % compare to VRTX and REGN?
According to the Drug Manufacturers industry distribution chart, Panion & Bf Biotech ranks #303 out of 961 companies for Pretax Margin %. This puts Panion & Bf Biotech in the upper half of its industry. The industry median Pretax Margin % is 7.28. Panion & Bf Biotech's value of 13.47% is 85% above this benchmark. Historically, Panion & Bf Biotech's own Pretax Margin % has ranged from 5.70 to 17.35 over the past decade. While the company's 10-year median is 12.07 vs. the industry median of 7.28, Panion & Bf Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panion & Bf Biotech's current Pretax Margin % of 13.47% is 85% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Panion & Bf Biotech and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panion & Bf Biotech's current Pretax Margin % is 13.47%, which is 12% above median its own 10-year median of 12.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$96.03, compared to a current price of NT$60.90 — trading 36.6% below its estimated fair value. The current Pretax Margin % is 13.47%, which is 12% above median its 10-year median of 12.07 and 85% above the Drug Manufacturers industry median of 7.28. Panion & Bf Biotech's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current Pretax Margin % is 13.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?
Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued.
The current stock price of NT$60.90 is trading 36.6% below its estimated GF Value™ of NT$96.03.
GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1760:
Pretax Margin %: 13.47% (12% above median its 10-year median of 12.07)
GF Value™: NT$96.03 vs. price of NT$60.90 (36.6% below fair value)
Industry Position: 85% above the Drug Manufacturers median (#303 of 961)
No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
74GF Score
Get the complete analysis for TPE:1760
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1760 has been successfully added to your 
